Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies
Clinical trial NCT02017613 · COMPLETED
Trial details
- NCT number
- NCT02017613
- Sponsor
- Rhizen Pharmaceuticals SA
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2013-11-01
- Primary completion
- 2016-05-01
- Enrollment
- 35
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.